BioCentury
ARTICLE | Clinical News

Ad26: Phase II started

July 27, 2015 7:00 AM UTC

Bavarian Nordic A/S (CSE:BAVA, Kvistgaard, Denmark) said the Oxford Vaccines Group of the University of Oxford (Oxford, U.K.) began a double-blind, U.K. and French Phase II trial to evaluate the company’s MVA-BN Filo vaccine and Johnson & Johnson’s Ad26.ZEBOV vaccine in 612 healthy volunteers. Subjects will receive intramuscular AD26.ZEBOV or placebo on day 1 and then intramuscular MVA-BN File or placebo on days 29, 57 or 85. An African Phase II trial is slated to start this quarter. ...